ME02814B - Nova so abeksinostata, sa njom povezani kristalni oblik, postupak pripreme i farmaceutske supstance koje ih sadrže - Google Patents
Nova so abeksinostata, sa njom povezani kristalni oblik, postupak pripreme i farmaceutske supstance koje ih sadržeInfo
- Publication number
- ME02814B ME02814B MEP-2017-139A MEP2017139A ME02814B ME 02814 B ME02814 B ME 02814B ME P2017139 A MEP2017139 A ME P2017139A ME 02814 B ME02814 B ME 02814B
- Authority
- ME
- Montenegro
- Prior art keywords
- abexinostat
- crystalline form
- tosylate
- expressed
- water
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims 14
- 229950008805 abexinostat Drugs 0.000 claims 14
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- XMXZUHOHUKWCJK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-n-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 XMXZUHOHUKWCJK-UHFFFAOYSA-N 0.000 claims 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 238000001237 Raman spectrum Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000001875 carbon-13 cross-polarisation magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (18)
1. Tozilat N-hidroksi-4-{2-[3-(N,N-dimetilaminometil)benzofuran- 2- ilkarbonilamino]etoksi}benzamida ili jedan od njegovih solvata.
2. So prema patenom zahtjevu 1 iz op!te formule (ll): H3C-oSO,H ..N \ (TI) o HN \ OH
3. Kristalini oblik l tozilata abeksinostata prema jednom od patentnih zahtjeva 1 ili 2, naznačen time što ima dijagram rendgenske difrakcije praha sa sledećim linijama difrakcije (Bragov ugao 2 teta, izraženo u stepenima ± 0,2•): 6,50; 9,94; 11,35; 12,33; 14,08; 18,95; 21,08; 27,05.
4. Kristalni oblik l tozilata abeksinostata prema patentnom zahtjevu 3, naznačen time što ima dijagram rendgenske difrakcije praha sa sledećim linijama difrakcije (Bragov ugao 2 teta, izraženo u stepenima± 0,2•): 6,50; 9,94; 11,35; 12,33; 14,08; 18,95; 19,61; 19,96; 21,08; 22,82; 23,61; 27,05.
5. Kristalni oblik l tozilata abeksinostata prema patentnom zahtjevu 3 ili 4, naznačen time što ima sljedeći dijagram rendgenske difrakcije praha izmeren na PANalytical X'Pert Pro MPD difraktometru sa detektorom X'Celerator i izražen u smislu položaja linije (Bragov ugao 2, izraženo u stepenima ± 0,2•) i d interretikularno rastojanje d (izraženo u A): • Linija br. Ugao 2 teta (stepeni) lnterretlkularno rastojanje (A) 1 2 3 4 5 6 7 8 9 10 11 12 6,50 9,94 11,35 12,33 14,08 18,95 19,61 19,96 21,08 22,82 23,61 27,05 13,581 8,894 7,789 7,173 6,285 4,683 4,526 4,449 4,215 3,897 3,768 3,296
6. Kristalni oblik l tozilata abeksinostata prema jednom od patentnih zahtjeva 3 do 5, naznačen time što ima Ramanov spektar sa značajnim vršnim vrednostima na poziciji 1608 cm·1.
7. Kristalni oblik l tozilata abeksinostata prema jednom od patentnih zahtjeva 1 do 6, naznačen time što ima Ramanov spektar sa značajnim vršnim vrednostima na pozicijama 940 cm·1, 1088 cm-1, 1132 cm·1, 1242 cm-1, 1360 cm·1, 1608 cm-1.
8. Kristalni oblik l tozilata abeksinostata prema jednom od patentnih zahtjeva 1 ili 2, naznačen time što ima 13c CP/MAS NMR spektar čvrstog stanja sa sledećim vršnim vrednostima (izraženimuppm±0,2ppm): 121,2ppm,122,1 ppm,123,5ppm 126,0ppm,126,8ppm,128,2 ppm, 128,9 ppm, 143,4 ppm, 144,6 ppm, 153,8 ppm, 159 ppm, 161,2 ppm i 162,1 ppm.
9. Kristalni oblik l tozilata abeksinostata prema patentnom zahtevu 8, naznačen time što ima 13c CP/MAS NMR spektar čvrstog stanja sa sledećim vršnim vrednostima (izraženo u ppm ± 0,2 ppm): Vr na vrednost Hemljskl pomak (ppm) Vr na vrednost Hemijskl pomak (ppm) 1 2 3 4 5 6 7 8 g 162,1 161,2 159,0 153,8 144,6 143,4 128,9 128,2 126,8 10 11 12 13 14 15 16 17 18 126,0 123,5 122,1 121,3 65,9 50,6 46,9 45,0 21,9 • •
10.Farmaceutska supstanca koja sadrži tozilat abeksinostata prema jednom od patentnih zahtjeva 1 ili 2 kao aktivni sastojak u vezi sa jednim ili više farmaceutski prihvatljivih ekscipijenata.
11.Farmaceutska supstanca koja sadržikristalni oblik l tozilata abeksinostata prema jednom od patentnih zahtjeva 3 do 9 kao aktivni sastojak u vezi sa jednim ili više farmaceutski prihvatljivih ekscipijenata.
12.Farmaceutska supstanca prema patentnom zahtjevu 1O do 11 za upotrebu u lečenju kancera.
13.Farmaceutska supstanca predviđena da se koristi prema jednom od patentnih zahtjeva 1O do12 u kojima je kancer karcinom, tumor, neoplazam, limfom, melanom, gliom, sarkom ili blastom.
14.Postupak za pripremu kristalnog oblika l tozilata abeksinostata prema jednom od patentnih zahtjeva 3 do 9, u kojima je abeksinostat kristalizovan u prisustvu paratoluensulfonske kiseline u polarnom medijumu.
15.Postupak za pripremu kristalnog oblika l tozilata abeksinostata prema patentnom zahtjevu 14, u kom se polarni medijum sastoji od jednog ili više rastvarača izabranih iz vode, alkohola, ketona i estara.
16.Postupak za pripremu kristalnog oblika l tozilata abeksinostata prema patentnom zahtevu 15, u kom je polarni medijum binarna mešavina, u kojoj je jedan od sastavnih delova voda.
17.Postupak za pripremu kristalnog oblika l tozilata abeksinostata prema patentnom zahljevu 16, u kom je polarni medijum binarna mešavina izabrana iz: acetona/vode, etanola/vode, izopropanola/vode i metil etil ketona/vode.
18.Postupak za pripremu kristalnog oblika l tozilata abeksinostata prema jednom od patentnih zahtjeva 14 do 17, u kom je kristalizacija aktivirana veoma malom količinom kristalnog oblika l tozilata abeksinostata. l
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772191P | 2013-03-04 | 2013-03-04 | |
| FR1351898A FR3002733B1 (fr) | 2013-03-04 | 2013-03-04 | Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP14711833.5A EP2964622B1 (fr) | 2013-03-04 | 2014-03-03 | Nouveau sel de l'abexinostat, forme cristalline associee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PCT/FR2014/050455 WO2014135776A1 (fr) | 2013-03-04 | 2014-03-03 | Nouveau sel de l'abexinostat, forme cristalline associee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02814B true ME02814B (me) | 2018-01-20 |
Family
ID=48521256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-139A ME02814B (me) | 2013-03-04 | 2014-03-03 | Nova so abeksinostata, sa njom povezani kristalni oblik, postupak pripreme i farmaceutske supstance koje ih sadrže |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US9115108B2 (me) |
| EP (2) | EP2964622B1 (me) |
| JP (2) | JP6449177B2 (me) |
| CN (2) | CN109734690B (me) |
| AR (1) | AR094935A1 (me) |
| AU (2) | AU2014224456B2 (me) |
| BR (1) | BR112015021443A2 (me) |
| CA (1) | CA2903369C (me) |
| CL (1) | CL2015002488A1 (me) |
| CR (1) | CR20150456A (me) |
| CY (1) | CY1119147T1 (me) |
| DK (1) | DK2964622T3 (me) |
| DO (1) | DOP2015000215A (me) |
| EA (2) | EA039113B1 (me) |
| ES (1) | ES2632471T3 (me) |
| FR (1) | FR3002733B1 (me) |
| GE (1) | GEP201706760B (me) |
| HR (1) | HRP20171041T1 (me) |
| HU (1) | HUE035299T2 (me) |
| IL (1) | IL241038B (me) |
| JO (1) | JO3402B1 (me) |
| LT (1) | LT2964622T (me) |
| MA (1) | MA38423B1 (me) |
| ME (1) | ME02814B (me) |
| MX (1) | MX355436B (me) |
| MY (1) | MY192027A (me) |
| NI (1) | NI201500122A (me) |
| PE (1) | PE20151591A1 (me) |
| PL (1) | PL2964622T3 (me) |
| PT (1) | PT2964622T (me) |
| RS (1) | RS56224B1 (me) |
| SG (1) | SG11201506952YA (me) |
| SI (1) | SI2964622T1 (me) |
| SM (1) | SMT201700351T1 (me) |
| TN (1) | TN2015000367A1 (me) |
| TW (1) | TWI506023B (me) |
| UA (1) | UA118550C2 (me) |
| UY (1) | UY35356A (me) |
| WO (1) | WO2014135776A1 (me) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| JP6178861B2 (ja) | 2012-11-02 | 2017-08-09 | ファイザー・インク | ブルトン型チロシンキナーゼ阻害剤 |
| FR3002733B1 (fr) | 2013-03-04 | 2015-08-14 | Servier Lab | Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| FR3025196B1 (fr) * | 2014-09-03 | 2019-09-06 | Pharmacyclics, Inc. | Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN107001307A (zh) * | 2014-09-03 | 2017-08-01 | 药品循环有限责任公司 | 3‑[(二甲基氨基)甲基]‑n‑{2‑[4‑(羟基氨基甲酰基)苯氧基]乙基}‑1‑苯并呋喃‑2‑甲酰胺的新颖的盐、有关的结晶形式、用于制备其的方法及包含其的药物组合物 |
| FR3025197B1 (fr) * | 2014-09-03 | 2019-09-06 | Pharmacyclics, Inc. | Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2017011314A1 (en) * | 2015-07-10 | 2017-01-19 | Paharmacyclics Llc | Btk and hdac combinations |
| EP4351734A1 (en) | 2021-06-10 | 2024-04-17 | Teva Pharmaceuticals International GmbH | Solid state forms of abexinostat and process for preparation thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3038004A (en) * | 1958-04-18 | 1962-06-05 | Burroughs Wellcome Co | Quaternary ammonium compounds |
| GB0020721D0 (en) * | 2000-08-22 | 2000-10-11 | Merck Sharp & Dohme | Therapeutic agents |
| SI1611088T1 (sl) * | 2003-04-07 | 2009-12-31 | Pharmacyclics Inc | Hidroksamati kot terapevtska sredstva |
| US20090270497A1 (en) * | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| US8603521B2 (en) * | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| WO2011036647A1 (en) * | 2009-09-24 | 2011-03-31 | Ranbaxy Laboratories Limited | Process for the preparation of sorafenib tosylate |
| WO2013039956A2 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating mood disorders |
| FR3002733B1 (fr) | 2013-03-04 | 2015-08-14 | Servier Lab | Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-03-04 FR FR1351898A patent/FR3002733B1/fr active Active
-
2014
- 2014-02-18 JO JOP/2014/0040A patent/JO3402B1/ar active
- 2014-02-27 UY UY0001035356A patent/UY35356A/es not_active Application Discontinuation
- 2014-02-28 AR ARP140100648A patent/AR094935A1/es unknown
- 2014-03-03 SG SG11201506952YA patent/SG11201506952YA/en unknown
- 2014-03-03 MA MA38423A patent/MA38423B1/fr unknown
- 2014-03-03 MX MX2015011566A patent/MX355436B/es active IP Right Grant
- 2014-03-03 HU HUE14711833A patent/HUE035299T2/en unknown
- 2014-03-03 PL PL14711833T patent/PL2964622T3/pl unknown
- 2014-03-03 RS RS20170687A patent/RS56224B1/sr unknown
- 2014-03-03 EP EP14711833.5A patent/EP2964622B1/fr active Active
- 2014-03-03 PE PE2015001875A patent/PE20151591A1/es unknown
- 2014-03-03 SM SM20170351T patent/SMT201700351T1/it unknown
- 2014-03-03 EP EP17166690.2A patent/EP3252044A1/fr not_active Withdrawn
- 2014-03-03 ME MEP-2017-139A patent/ME02814B/me unknown
- 2014-03-03 JP JP2015560740A patent/JP6449177B2/ja active Active
- 2014-03-03 DK DK14711833.5T patent/DK2964622T3/en active
- 2014-03-03 CN CN201811248983.5A patent/CN109734690B/zh active Active
- 2014-03-03 UA UAA201508558A patent/UA118550C2/uk unknown
- 2014-03-03 US US14/195,186 patent/US9115108B2/en active Active
- 2014-03-03 CA CA2903369A patent/CA2903369C/en active Active
- 2014-03-03 ES ES14711833.5T patent/ES2632471T3/es active Active
- 2014-03-03 PT PT147118335T patent/PT2964622T/pt unknown
- 2014-03-03 BR BR112015021443A patent/BR112015021443A2/pt not_active IP Right Cessation
- 2014-03-03 WO PCT/FR2014/050455 patent/WO2014135776A1/fr not_active Ceased
- 2014-03-03 EA EA201891023A patent/EA039113B1/ru unknown
- 2014-03-03 AU AU2014224456A patent/AU2014224456B2/en active Active
- 2014-03-03 LT LTEP14711833.5T patent/LT2964622T/lt unknown
- 2014-03-03 EA EA201591530A patent/EA030689B1/ru unknown
- 2014-03-03 MY MYPI2015002172A patent/MY192027A/en unknown
- 2014-03-03 HR HRP20171041TT patent/HRP20171041T1/hr unknown
- 2014-03-03 SI SI201430278T patent/SI2964622T1/sl unknown
- 2014-03-03 TW TW103107081A patent/TWI506023B/zh active
- 2014-03-03 CN CN201480012148.5A patent/CN105263917B/zh active Active
- 2014-03-03 GE GEAP201413950A patent/GEP201706760B/en unknown
-
2015
- 2015-07-13 US US14/798,412 patent/US20150315167A1/en not_active Abandoned
- 2015-08-26 TN TN2015000367A patent/TN2015000367A1/fr unknown
- 2015-09-02 IL IL241038A patent/IL241038B/en active IP Right Grant
- 2015-09-02 CR CR20150456A patent/CR20150456A/es unknown
- 2015-09-04 DO DO2015000215A patent/DOP2015000215A/es unknown
- 2015-09-04 CL CL2015002488A patent/CL2015002488A1/es unknown
- 2015-09-04 NI NI201500122A patent/NI201500122A/es unknown
-
2017
- 2017-01-12 US US15/405,021 patent/US10150748B2/en active Active
- 2017-07-06 CY CY20171100723T patent/CY1119147T1/el unknown
-
2018
- 2018-04-26 AU AU2018202881A patent/AU2018202881B2/en active Active
- 2018-12-05 JP JP2018228486A patent/JP6720280B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02814B (me) | Nova so abeksinostata, sa njom povezani kristalni oblik, postupak pripreme i farmaceutske supstance koje ih sadrže | |
| IL267048A (en) | Menstrual modulation of transmembrane conductivity in cystic fibrosis, pharmaceutical preparations, treatment methods, and process for the formation of the modulator | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| HRP20120066T1 (hr) | Kalijeva sol inhibitora hiv integraze | |
| EP4420732A3 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| NZ742200A (en) | Treatment of osteoarthritis | |
| HRP20160208T4 (hr) | Polimorfi dasatiniba i postupak za njihovu pripremu | |
| WO2012007877A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
| JP2017522276A5 (me) | ||
| MX2016016538A (es) | Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa. | |
| FI4293009T3 (fi) | Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| MY195177A (en) | Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof | |
| JP2019519512A5 (me) | ||
| HRP20210667T1 (hr) | Kristalni oblici antagonista androgenog receptora, postupak pripreme i njihova upotreba | |
| MX379704B (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. | |
| FR2981933B1 (fr) | Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
| HRP20230563T1 (hr) | Nova sol bcl-2 inhibitora, srodni kristalni oblik, postupak za pripravu istih i farmaceutski pripravci koji ih sadrže | |
| JP2016512541A5 (me) | ||
| TN2012000619A1 (fr) | Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent | |
| HRP20161691T1 (hr) | Derivati ariletinila |